Investment Rating - The report maintains an investment rating of "Buy-A" with a target price of HKD 108.0, while the current stock price is HKD 87.60 [3][5]. Core Insights - The core logic of the report emphasizes the significant potential of the second-generation IO cornerstone drug PD-1/IL-2α dual antibody for overseas licensing, which is expected to drive the company's transformation from a China-focused biopharma to a global biopharma [1][2]. - The company has established a robust pipeline of innovative drugs, primarily focused on oncology, with additional products in metabolic, autoimmune, and ophthalmic fields [1][10]. - The report highlights the promising overseas licensing potential of IBI363, the PD-1/IL-2α dual antibody, which is positioned as a new cornerstone drug in IO therapy [2][3]. Summary by Sections 1. Second-Generation IO Potential - The report identifies the PD-1/IL-2α dual antibody as a key product with substantial overseas licensing potential, which could serve as a foundation for the company's global transformation [2][3]. 2. Innovative Drug Layout - The company has developed a rich pipeline of innovative drugs, with a focus on oncology, metabolic diseases, autoimmune diseases, and ophthalmology [1][22]. - In the oncology sector, the company has 12 approved drugs and several in late-stage clinical trials, including the PD-1/IL-2 dual antibody [23][24]. 3. Heavyweight Products in Domestic Market - The report notes that the weight-loss and diabetes drug, Ma Shidu Peptide, has a large domestic market and a first-mover advantage as it has already been approved for weight loss and is expected to receive approval for diabetes soon [2][4]. 4. Future Key Focus Areas - The report outlines several key factors driving the company's transition to a global biopharma, including the overseas licensing of IBI363 and the projected sales revenue of 20 billion yuan by 2027 [3][6]. - The company anticipates revenue growth from existing and pipeline products, projecting revenues of 11.9 billion yuan, 15.75 billion yuan, and 20.4 billion yuan for 2025, 2026, and 2027, respectively [3][6]. 5. Financial Projections and Valuation - The report provides financial forecasts, estimating net profits of 700 million yuan, 1.84 billion yuan, and 2.92 billion yuan for 2025, 2026, and 2027, respectively [6][19]. - A DCF valuation method estimates the company's value at approximately 168.7 billion yuan [3][6].

Investment Rating - The report maintains a "Buy" rating for Chow Tai Fook [6] Core Views - Chow Tai Fook's FY2026 Q1 same-store sales decline continues to narrow, with expectations for ongoing improvement [1] - The company is focusing on optimizing product structure and closing underperforming stores, which is expected to enhance sales performance [2] - E-commerce sales have shown strong growth, with a 27% year-on-year increase in FY2026 Q1 [2] - The company anticipates a 3% revenue growth for FY2026, with a slight decline in operating profit [3] Summary by Sections Financial Performance - For FY2026 Q1, Chow Tai Fook's overall RSV decreased by 1.9%, with mainland China RSV down by 3.3% [1] - The company closed 311 underperforming stores, bringing the total to 5,963 stores in mainland China [1] - The retail sales of gold products increased by 20.8%, contributing to the improvement in same-store sales [1] E-commerce Growth - Chow Tai Fook's e-commerce sales in mainland China grew by 27% year-on-year, accounting for 7.6% of total sales [2] - The company is leveraging promotional events like the 618 sales to boost e-commerce performance [2] Regional Performance - In FY2026 Q1, sales in Hong Kong and Macau increased by 7.8%, with Macau showing a notable 9.5% growth in same-store sales [2] Revenue and Profit Forecast - The company expects FY2026 revenue to grow by approximately 3%, while operating profit is projected to decline by 2% to HKD 14.4 billion [3] - Chow Tai Fook's net profit for FY2026 is forecasted to increase by 26% to HKD 7.45 billion [3]

Investment Rating - The report maintains a "Buy" rating for Kingsoft Software [3][5] Core Views - Kingsoft Software continues to experience steady revenue growth, with Q1 revenue reaching 2.34 billion RMB, a year-on-year increase of 9%. The office and gaming segments contribute 56% and 44% to the total revenue, respectively [1] - The company's gross margin for the quarter is approximately 82%, reflecting a 1 percentage point increase year-on-year [1] - R&D expenses for the quarter are around 830 million RMB, up 16% year-on-year, primarily due to investments in AI capabilities and new game categories [1] - The report forecasts revenue growth driven by both office and gaming segments, estimating revenues of 11.4 billion, 12.9 billion, and 14.6 billion RMB for 2025, 2026, and 2027, respectively [3] Summary by Sections Office Segment - Kingsoft Office recorded Q1 revenue of 1.301 billion RMB, a year-on-year increase of 6.22%. The personal business segment generated 857 million RMB, growing by 10.86% [2] - WPS 365 business revenue reached 151 million RMB, marking a significant year-on-year growth of 62.59% [2] - WPS software business revenue declined by 20.99% to 262 million RMB, mainly due to new procurement processes affecting sales [2] Gaming Segment - The gaming and other business revenue for Q1 was approximately 1.04 billion RMB, a year-on-year increase of 14%, driven by contributions from games like "Dust White Zone" and "Jian Wang 3" [2] - The new game "Limitless Machine" launched on July 2, has received positive feedback, ranking fifth on Steam's global wishlist [2] Financial Projections - The report projects net profits for 2025, 2026, and 2027 to be 1.88 billion, 2.46 billion, and 2.85 billion RMB, respectively, with corresponding growth rates of 21%, 31%, and 16% [4][3] - The estimated P/E ratio for 2026 is 17.4, with a target valuation of approximately 49.1 billion RMB, corresponding to a target price of around 40 HKD [3]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][5]. Core Views - The company is leveraging its energy-based medical aesthetics equipment to expand into multiple beauty categories, establishing a diversified ecosystem in the global medical aesthetics market [1][15]. - The long-acting botulinum toxin product, DAXXIFY, is expected to launch in 2025-2026, which could significantly enhance market recognition and sales due to its extended efficacy [3][19]. Summary by Sections Company Overview - The company began its journey in 2013 with the acquisition of Alma Lasers and has since expanded its business from energy-based medical aesthetics to include injection products, dental care, and personal care, enhancing its global market influence [1][15]. Main Business - The company aims to create a comprehensive medical aesthetics industry chain, providing one-stop beauty solutions that encompass energy-based medical aesthetics, injection aesthetics, dental care, and personal care [15][24]. Financial Analysis - The company experienced a temporary decline in revenue growth due to macroeconomic factors and strategic adjustments, with a projected revenue of $3.49 billion in 2024, reflecting a decrease of 2.83% [25][30]. - The net profit is also expected to decline to $0.25 billion in 2024, down 20.23% from the previous year, primarily due to increased sales expenses from transitioning to a direct sales model [25][30]. Energy-Based Equipment - The global market for energy-based medical aesthetics devices reached $5.7 billion in 2022, with a projected CAGR of 13.8% from 2023 to 2030, driven by the growing demand for non-invasive aesthetic procedures [2][44]. - North America is the largest market, accounting for 35.4% of global sales, while the Asia-Pacific region is expected to see the highest growth rate at 15.6% CAGR from 2023 to 2030 [2][44]. Long-Acting Botulinum Toxin - The long-acting botulinum toxin product, DAXXIFY, is anticipated to address consumer concerns regarding frequent injections, with a median duration of effect lasting 6 to 9 months, positioning it favorably in the market [2][3]. Other Business Segments - The company is actively expanding into dental care and personal care, aiming to broaden its long-term growth potential [19][24].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase exceeding 15% over the next six months [6]. Core Insights - The company is projected to achieve a revenue of no less than 1.45 billion yuan in the first half of 2025, representing a growth rate of at least 27%. Adjusted net profit is expected to be no less than 175 million yuan, with a growth rate of at least 33% [1]. - The company's dual growth strategy, driven by both organic and external expansion, is effectively supporting steady revenue growth. Internally, the company is enhancing its business model and operational efficiency, while externally, it is committed to scaling through mergers and acquisitions [2]. - The optimization of the shareholding structure, high dividend commitments, and stock incentive plans reflect the company's confidence in its long-term development [3]. Financial Summary - The company’s projected revenues for 2025-2027 are 3.064 billion yuan, 3.344 billion yuan, and 3.645 billion yuan, respectively. Corresponding net profits are expected to be 320 million yuan, 362 million yuan, and 413 million yuan, with price-to-earnings ratios of 20, 18, and 16 times [3][5]. - The financial outlook shows a significant increase in revenue and net profit, with a projected revenue growth of 19.13% in 2025 and 9.13% in 2026 [5]. - The company is expected to maintain a dividend payout ratio of no less than 50% of net profit from 2025 to 2027, enhancing shareholder returns [3].

证券研究报告 港股通 中国联塑 (2128 HK) 城市更新催化，高标农田拉动 | 华泰研究 | | | 更新报告 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2025 年 | 7 月 | 23 日│中国香港 | 其他建材 | 目标价(港币): | 5.89 | 据新华社，7 月 14-15 日，中央城市工作会议在北京举行，指出城市发展正 从大规模增量扩张转向存量提质增效为主。我们认为人口增长和城镇化率等 指标发展达到一定阶段后，增量建设将转向存量更新为主，城市更新有望迎 来持续催化阶段，我们认为其中的管网改造环节有望拉动市政塑管需求，叠 加近两年第一产业投资增速稳健，中国联塑介入农业用塑管领域成效显现， 考虑到公司工程端市占率较高，我们认为公司有望充分受益，我们上调其目 标价至 5.89 港元（前值 4.36 港元，上调幅度为 35%），维持"买入"。 城市更新为提质增效抓手，存量建筑物规模庞大 本次中央城市工作会议强调以城市更新为重要抓手，高质量开展城市更新， 稳步推进城中村改造和危旧房改造，我们认为城市更新有望在"十五五"期 间接 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 27.06 [6]. Core Views - The company is expected to achieve a net profit of USD 90 million to 100 million for the first half of 2025, representing a year-on-year increase of 46% to 62%. Adjusted net profit, excluding non-recurring gains from the disposal of automotive equity, is projected to be USD 70 million to 80 million, reflecting a year-on-year growth of 14% to 30% [1][5]. - The company's strong profit performance is attributed to the steady growth of its proprietary brand business represented by EGO, divestiture of non-core assets, and favorable currency fluctuations. Despite external tariff disruptions, the company's operational resilience remains prominent [1][2]. Summary by Sections Main Business Operations - The company has shown resilience in operations despite concerns over US-China trade tariffs, with North American revenue expected to reach USD 1.293 billion in 2024, accounting for 72.9% of total revenue. New tariffs of 20% on fentanyl and 10% on reciprocal tariffs have been introduced since 2025. To mitigate tariff risks, the company has implemented proactive measures such as pre-stocking in overseas warehouses, adaptive pricing strategies, and accelerated overseas capacity expansion [2]. Asset Divestiture - The company signed an agreement to sell its automotive equity for RMB 570 million, which is expected to generate an investment gain of USD 20 million. The divestiture will eliminate the negative impact of equity losses from joint ventures, which amounted to USD 18.3 million and USD 17.3 million in 2023 and 2024, respectively, thereby enhancing the profitability on the balance sheet [3]. Long-term Outlook - As a leading global brand in electric tools and lithium battery outdoor power equipment (OPE), the company’s EGO brand has shown strong growth momentum, with a projected 2 percentage point increase in market share in the US for 2024. The trend towards lithium OPE is clear, driven by improved product performance and reduced total cost of ownership. The company is well-positioned to benefit from this trend, especially in the developed markets of North America and Europe, where OPE consumption is considered essential [4]. Profit Forecast and Valuation - The report maintains profit forecasts, projecting net profits of USD 148 million, USD 174 million, and USD 201 million for 2025 to 2027, respectively, with corresponding EPS of USD 0.29, USD 0.34, and USD 0.39. The target price is set at 12 times the expected PE for 2025, resulting in a target price of HKD 27.06 [5][9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [4][6]. Core Views - The company is expected to achieve revenue of 1.2-1.24 billion yuan in the first half of 2025, representing a year-on-year decline of 1.5%-4.7%. However, net profit is projected to increase to 90-113 million yuan, a growth of 55.2%-94.8% compared to 58 million yuan in the first half of 2024 [2][4]. - The company has implemented multi-dimensional operational adjustments, leading to gradual improvements in performance. The revenue decline has narrowed significantly compared to 2024, with same-store sales returning to positive growth [3][4]. Summary by Sections Revenue and Profit Forecast - The company is projected to generate revenues of 2.715 billion yuan in 2025, with a growth rate of 10.8%. The net profit forecast for 2025 is 143 million yuan, reflecting a growth rate of 45.1% [5][10]. Operational Adjustments - The company has closed underperforming stores and improved employee incentives, resulting in a recovery of same-store sales. The management structure has been streamlined for quicker decision-making [3][4]. - A focus on enhancing the membership system has been established, which has led to increased average transaction values and customer retention rates [3][4]. Strategic Initiatives - The company is pursuing brand rejuvenation and adjusting store formats to attract younger consumers. Plans include enhancing store displays and customer experience in key locations [3][4]. - New distribution channels are being developed to improve capacity utilization and operational efficiency, with a focus on supermarkets and convenience stores [3][4]. Valuation Metrics - The updated earnings per share (EPS) estimates for 2025-2027 are 0.07, 0.08, and 0.09 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 36, 30, and 25 times [4][10].

研究报告 Research Report 23 Jul 2025 TCL 电子 TCL Electronics Holdings (1070 HK) 25H1 业绩优异，MiniLED 引领全球 Excellent Performance in 25H1, MiniLED Leading Global Trends [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.28 目标价 HK$13.65 HTI ESG 4.5-4.2-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$25.92bn / US$3.30bn 日交易额 (3 个月均值) US$11.70mn 发行股票数目 2,521mn 自由流通股 (%) 34% 1 年股价最高最低值 HK$11.04-HK$4.40 注：现价 HK$10.28 为 2025 年 07 月 22 日收盘价 资料来源： Fa ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a year-on-year growth of not less than 30% in net profit attributable to shareholders for the first half of 2025, with adjusted net profit projected to grow approximately 65%-72% to 450-469 million yuan, exceeding expectations [7] - The core business of image and design products is showing significant operational leverage, with an increase in paid subscription users driving rapid revenue growth. The gross margin of this business is high, and as its revenue share increases, it is expected to enhance overall gross profit and margin [7] - The introduction of AI features in products like beauty cameras and Meitu Xiuxiu has led to significant user engagement, with expectations for substantial growth in overseas monthly active users (MAU) [7] - The company is focusing on AI productivity tools, particularly in e-commerce scenarios, with a strategic partnership with Alibaba expected to accelerate user expansion [7] - The company forecasts adjusted net profits of 854.22 million yuan, 1,176.94 million yuan, and 1,473.84 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 52, 38, and 30 [1][7] Financial Summary - Total revenue for 2023 is projected at 2,696 million yuan, with a year-on-year growth of 29.27%. For 2024, revenue is expected to reach 3,341 million yuan, growing by 23.93% [1] - Adjusted net profit for 2023 is estimated at 368.30 million yuan, with a significant year-on-year increase of 233.17%. The adjusted EPS for 2023 is projected at 0.08 yuan per share [1] - The company’s total assets are expected to grow from 7,046.68 million yuan in 2024 to 10,077.93 million yuan by 2027, indicating a strong growth trajectory [8]